Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
With
Nektar Therapeutics
Ono Pharmaceutical Co., Ltd.
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Histologic or cytological confirmation of an advanced (metastatic and/or unresectable) malignant solid tumor with measurable disease per RECIST v1.1.
Life expectancy \>12 weeks.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
You may not be if
Active, known or suspected autoimmune disease.
History of organ transplant that requires use of immune suppressive agents.
Prior surgery or radiotherapy within 14 days of Cycle 1 Day 1. Participants must have recovered from all radiation-related, toxicities and not requiring corticosteroids.
Clareo Health | An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors
